ArticleJournal of molecular histology2026
LncRNA TRHDE-AS1 functions as a tumor suppressor in ovarian cancer via the miR-17-5p/PIK3R1 ceRNA regulatory axis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to explore the expression, biological function, and regulatory mechanism of lncRNA TRHDE‑AS1 in ovarian cancer (OC). The GEO dataset GSE119056 and the GEPIA2 database were used to assess the expression level of TRHDE-AS1 in OC tissues. In vitro experiments, including RT-qPCR, CCK-8, Transwell, and dual-luciferase reporter assays, were performed in SKOV3 and 3AO cells to clarify the biological function of TRHDE-AS1 and its ceRNA regulatory network involving miR-17-5p and PIK3R1. TRHDE-AS1 was downregulated in OC tissues and cell lines. TRHDE-AS1 inhibited the proliferation, migration, and invasion of OC cells. Mechanistically, TRHDE-AS1 was predominantly localized in the cytoplasm and directly bound to miR-17-5p. miR-17-5p targeted the 3'UTR of PIK3R1 and negatively regulates its expression. TRHDE‑AS1 upregulated PIK3R1 expression by sponging miR‑17‑5p. Functional rescue assays confirmed that miR‑17‑5p mimic reversed the tumor‑suppressive effects of TRHDE‑AS1 overexpression, while PIK3R1 overexpression restored these inhibitory effects. TRHDE-AS1 functions as a tumor suppressor in OC by regulating the miR-17-5p/PIK3R1 axis, which provides a potential molecular target for OC targeted therapy.
Indexed as
Identifiers
42461466What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.